Chemokines are small immune system proteins mediating leukocyte migration and activation, and are important in many aspects of health and diseases. Some chemokines also have the ability to block HIV-1 infection by binding to the HIV-1 co-receptors CCR5 (CC chemokine receptor 5) and CXCR4 (CXC chemokine receptor 4). The first part of this work is to determine the mechanism of action of a human herpesvirus-8 encoded viral chemokine analog vMIP-II (viral macrophage inflammatory protein-II) by characterizing its interactions with endothelial surface glycosaminoglycans (GAGs) and cell surface receptors. Nuclear magnetic resonance (NMR), mutagenesis and molecular-docking were conducted and results show that vMIP-II tightly binds glycosaminoglycans using residues distributed along one face of the protein, such as R18, R46 and R48, and that there is a shift in the GAG binding site between the monomer and dimer form of vMIP-II where the N-terminus is involved in GAG binding for the dimer. This study, for the first time, provides a model that explains the mechanism of how quaternary structure affects chemokine-GAG binding. Mutagenesis and competition binding assays were conducted to study the receptor-binding mechanism of vMIP-II. Preliminary results suggest that vMIP-II uses the same positively charged binding surface comprising R18, K45, R46 and R48 to interact with the negatively charged N-termini of CCR5 and CXCR4. NMR studies on how vMIP-II interacts with N-terminal peptides of CCR5 and CXCR4 is on-going. The second part of this work was to rationally design HIV-1 entry inhibitors based on our knowledge of the mechanisms of chemokine-receptor binding and HIV-1 cell entry. We successfully designed two chimeric HIV entry inhibitors composed of CCR5-targeting RANTES variants (5P12-RANTES and 5P14-RANTES) linked to a gp41 targeting C-peptide, C37. In in vitro assays, chimeric inhibitors 5P12-linker-C37 and 5P14-linker-C37 showed the highest anti-viral potency yet published with IC50 values as low as 0.001 nM against certain virus strains. On human peripheral blood mononuclear cells, the chimeric inhibitors also exhibited very strong inhibition against R5-tropic and X4-tropic viruses, with IC50 values as low as 0.015 nM and 0.44 nM, respectively. A clear delivery mechanism was observed and characterized. These fully recombinant inhibitors can be easily produced at low cost and are excellent candidates for HIV microbicides.

Made available in DSpace on 2014-08-20T13:32:48Z (GMT). No. of bitstreams: 1 tese_silvana_beutinger_marchioro.pdf: 842737 bytes, checksum: 032d940f684cacf69ead32db6268d1cc (MD5) Previous issue date: 2013-06-27 / Mycoplasma hyopneumoniae (M. hyopneumoniae) is the causative agent of enzootic pneumonia (EP) in pigs, a chronic respiratory disease characterized by low mortality and high morbidity, responsible by significant economic losses in the pig industry worldwide. M. hyopneumoniae infection can be controlled by optimizing management practices and housing conditions, as well as with the use of antibiotics and vaccination. Commercial vaccines consist of adjuvanted inactivated whole cell preparations, and are frequently used worldwide in countries with an intensive pig production. The currently available vaccines are beneficial from an economic point of view, but they do not provide a sustainable control of the disease. They cannot prevent colonization of M. hyopneumoniae in the respiratory tract, and do not significantly reduce the transmission of the pathogen. Also, little is known about the exact mechanisms of the partial protection they induce. In this context, the general aims of this thesis were to assess the mode of the action of an existing commercial vaccine on the one hand and to develop and evaluate a new recombinant vaccine against M. hyopneumoniae on the other hand, looking for more effective strategies for disease control. For development of the recombinant vaccine a chimeric protein was developed and evaluated. This protein was based on proteins known to play a role in the adhesion and that were able to induce an immune response and a partial protection against M. hyopneumoniae infection when evaluated individually. From the studies described in this thesis, it can be concluded that intramuscular vaccination with an adjuvanted bacterin is able to stimulate both systemic and local immune responses, and that the new recombinant vaccine developed against EP might be promises strategies to control the disease. / Mycoplasma hyopneumoniae (M. hyopneumoniae) é o agente etiológico da pneumonia enzoótica (EP) suína, uma doença crônica de baixa mortalidade e alta morbidade, responsável por perdas econômicas significativas na cadeia suinícola em todo o mundo. A infecção por M. hyopneumoniae pode ser controlada pela otimização das práticas de manejo e das condições de alojamento, bem como com o uso de antibióticos e vacinação. Vacinas comerciais consistem em preparações de células inteiras inativadas do agente, fornecidas com adjuvante, e são frequentemente utilizadas em todo o mundo. As vacinas disponíveis atualmente são benéficas do ponto de vista econômico, mas elas não fornecem um controle sustentável da doença. Elas não previnem a colonização do M. hyopneumoniae no trato respiratório, e não reduzem significativamente a transmissão do agente patogênico. Além disso, pouco se sabe sobre os mecanismos exatos envolvidos na proteção que elas induzem. Desta forma, os objetivos gerais desta tese foram avaliar o modo de ação de uma vacina comercial existente e desenvolver e avaliar uma nova vacina recombinante contra M. hyopneumoniae, buscando estratégias mais eficazes para o controle da doença. Para o desenvolvimento desta vacina recombinante uma proteína quimérica foi produzida, baseada em proteínas envolvidas na adesão do agente e que foram capazes de induzir uma resposta imune e uma proteção parcial contra a infecção por M. hyopneumoniae quando avaliadas individualmente, e avaliada seu potencial protetor em teste de infecção experimental de suínos. A partir dos estudos descritos nesta tese, pode-se concluir que a vacinação intramuscular com uma bacterina comercial é capaz de estimular tanto uma resposta imune sistêmica quanto local, e que a nova vacina recombinante desenvolvida contra a EP pode ser considerada uma estratégia promissora para o controle da doença.

Saccharomyces yeasts are ideal candidates for genomic and evolutionary studies in eukaryotes due to their small genome, short generation time and availability of genomic data. Species freely hybridize producing viable but largely sterile cells. A hybridization event can be a swift mechanism for evolutionary innovation that if successful, may produce individuals fitter than either parents. It is largely unclear which mechanisms contribute to such hybrid vigour. This thesis investigated three mechanisms by which a natural hybrid may utilise one or both subgenomes to its advantage: recombination, the formation of chimeric protein complexes and the inheritance of mitochondrial DNA. Three strains of Saccharomyces pastorianus, a natural hybrid of Saccharomyces cerevisiae and Saccharomyces eubayanus, used in the lager fermentation process were sequenced using a NGS SOLiD platform. An analysis of recombination between each subgenome revealed the presence of 30 breakpoints, 28 of which are found within coding regions. Two breakpoints, present within the genes XRN1 and HSP82 have been reused in all three strains of S. pastorianus. This thesis investigated the formation of chimeric protein complexes in S. pastorianus by determining the configuration of protein complex-forming gene pairs to see whether they were mainly uni-specific, with all members belonging to the same parent, or chimeric, comprising one member from each parental species. A total of 21 pairwise protein complexes were found to be obligatorily chimeric in three strains of S. pastorianus. We used PCR-mediated gene deletion to recreate chimeric protein complexes in laboratory hybrids of S. cerevisiae and S. uvarum. The allelic configuration of one protein-complex forming gene pair, MLP2 and SPC110, impacted the growth of hybrid strains in a temperature-dependent manner. Finally, we looked at the mitochondrial inheritance in hybrids. Yeast hybrids can initially inherit mitochondrial DNA (mtDNA) from both parents, but rapidly become homoplasmic. To investigate the mechanisms influencing mtDNA inheritance, strains of Saccharomyces cerevisiae and Saccharomyces uvarum were crossed under different environmental conditions. The majority of hybrids inherited S. cerevisiae mtDNA when crossed in glycerol, a carbon source that can only be respired by yeast, in a range of temperatures. Those crossed in glucose, a fermentable source, did not show a preference for the inheritance of mtDNA at 30°, but at 10°C preferentially inherited S. uvarum mtDNA. In subsequent growth assays, hybrids with S. cerevisiae mtDNA grew better than those with S. uvarum mtDNA at 30°C and 20°C. However, at 10°C, the reverse was true: hybrids with S. uvarum mtDNA grew better that those with S. cerevisiae mtDNA, although only in glycerol. Overall this works sheds light on the molecular mechanisms contributing to fitness and evolutionary vigour in yeast hybrids.